StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) stock

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$18.17−0.40 (-2.15%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Structure Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Structure Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$220.29M. For fiscal 2025 it was -$222.20M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$222.20M–
FY2024Dec 31, 2024-$116.64M–
FY2023Dec 31, 2023-$79.49M–
FY2022Dec 31, 2022-$46.12M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$120.12M–
Q1 FY2026Mar 31, 2026$15.23M–
Q4 FY2025Dec 31, 2025-$64.42M–
Q3 FY2025Sep 30, 2025-$51.00M–
Q2 FY2025Jun 30, 2025-$54.56M–
Q1 FY2025Mar 31, 2025-$52.23M–
Q4 FY2024Dec 31, 2024-$36.47M–
Q3 FY2024Sep 30, 2024-$19.70M–
Q2 FY2024Jun 30, 2024-$26.39M–
Q1 FY2024Mar 31, 2024-$34.08M–
Q4 FY2023Dec 31, 2023-$21.73M–
Q3 FY2023Sep 30, 2023-$20.56M–
Q2 FY2023Jun 30, 2023-$16.89M–
Q1 FY2023Mar 31, 2023-$20.31M–
Q4 FY2022Dec 31, 2022-$12.03M–
Q3 FY2022Sep 30, 2022-$10.48M–
Q2 FY2022Jun 30, 2022-$10.10M–
Q1 FY2022Mar 31, 2022-$13.52M–

More Structure Therapeutics figures

See a number that looks wrong?